Phase 3 study of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis with F508del and gating or residual function mutations

Phase 3, randomised, double-blind trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second from baseline through Week 8. Started Jun 2019; status: completed.